| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $1,419,500 | 10 | 100 |
| Williams Paul Anthony | SVP, Products Business | 0 | $0 | 2 | $58,960 | $-58,960 |
| Katkin Keith | director | 0 | $0 | 1 | $128,183 | $-128,183 |
| Zoon Kathryn C | director | 0 | $0 | 1 | $144,453 | $-144,453 |
| Dayal Sujata Tyagi | director | 0 | $0 | 2 | $201,130 | $-201,130 |
| Richard Ronald | director | 0 | $0 | 1 | $263,077 | $-263,077 |
| Glessner Coleen | EVP, Quality & Ethics, and CPL | 0 | $0 | 1 | $306,080 | $-306,080 |
| DeGolyer Donald W | director | 0 | $0 | 2 | $317,616 | $-317,616 |
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Over the last 12 months, insiders at Emergent BioSolutions Inc. have bought $0 and sold $1.42M worth of Emergent BioSolutions Inc. stock.
On average, over the past 5 years, insiders at Emergent BioSolutions Inc. have bought $231,090 and sold $508,159 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 60,000 shares for transaction amount of $349,800 was made by PAPA JOSEPH C (President and CEO) on 2025‑05‑13.
| 2026-07-01 | Sale | Williams Paul Anthony | SVP, Products Business | 3,000 0.0059% | $8.40 | $25,200 | -12.56% | |
| 2026-05-01 | Sale | DeGolyer Donald W | director | 15,481 0.0297% | $8.40 | $129,994 | -6.14% | |
| 2026-05-01 | Sale | Dayal Sujata Tyagi | director | 13,761 0.0264% | $8.40 | $115,610 | -6.14% | |
| 2026-05-01 | Sale | Zoon Kathryn C | director | 17,202 0.033% | $8.40 | $144,453 | -6.14% | |
| 2026-04-30 | Sale | Katkin Keith | director | 15,481 0.0311% | $8.28 | $128,183 | -3.22% | |
| 2026-04-01 | Sale | Williams Paul Anthony | SVP, Products Business | 4,000 0.0078% | $8.44 | $33,760 | -4.18% | |
| 2025-12-05 | Sale | Richard Ronald | director | 21,984 0.041% | $11.97 | $263,077 | -30.25% | |
| 2025-11-10 | Sale | DeGolyer Donald W | director | 17,801 0.0342% | $10.54 | $187,623 | -23.66% | |
| 2025-11-07 | Sale | Dayal Sujata Tyagi | director | 8,552 0.0127% | $10.00 | $85,520 | -17.42% | |
| 2025-10-07 | Sale | Glessner Coleen | EVP, Quality & Ethics, and CPL | 30,608 0.0578% | $10.00 | $306,080 | -14.01% | |
| 2025-08-15 | Sale | Zoon Kathryn C | director | 7,086 0.0133% | $8.87 | $62,853 | -1.30% | |
| 2025-08-12 | Sale | DeGolyer Donald W | director | 7,844 0.0156% | $8.65 | $67,831 | -1.35% | |
| 2025-05-23 | Sale | Katkin Keith | director | 7,844 0.0142% | $6.30 | $49,417 | +36.33% | |
| 2025-05-13 | PAPA JOSEPH C | President and CEO | 60,000 0.1096% | $5.83 | $349,800 | +48.13% | ||
| 2025-03-12 | Sale | Fowler Neal Franklin | director | 35,000 0.0611% | $5.83 | $204,050 | +35.77% | |
| 2025-03-12 | Sale | Zoon Kathryn C | director | 10,000 0.0171% | $5.73 | $57,300 | +35.77% | |
| 2024-11-12 | Sale | DeGolyer Donald W | director | 25,000 0.0461% | $10.91 | $272,750 | -26.81% | |
| 2024-11-11 | Sale | White Marvin L | director | 14,287 0.0264% | $11.97 | $171,015 | -33.42% | |
| 2024-06-04 | Sale | Zoon Kathryn C | director | 10,000 0.021% | $6.11 | $61,100 | +47.75% | |
| 2024-05-29 | Sale | Zoon Kathryn C | director | 1,830 0.0035% | $4.61 | $8,436 | +77.05% |
| Williams Paul Anthony | SVP, Products Business | 159098 0.3084% | $987,998.58 | 0 | 2 | |
| Glessner Coleen | EVP, Quality & Ethics, and CPL | 144319 0.2797% | $896,220.99 | 0 | 1 | |
| DeGolyer Donald W | director | 129721 0.2514% | $805,567.41 | 0 | 4 | |
| Dayal Sujata Tyagi | director | 100563 0.1949% | $624,496.23 | 0 | 2 | |
| Richard Ronald | director | 98417 0.1907% | $611,169.57 | 0 | 26 | |
| Katkin Keith | director | 96294 0.1866% | $597,985.74 | 0 | 2 | |
| Zoon Kathryn C | director | 79941 0.1549% | $496,433.61 | 0 | 23 | |
| Intervac, L.L.C. | 10 percent owner | 6136794 11.8939% | $38.11M | 0 | 22 | |
| Biologika, L.L.C. | Member 13(d) group owning >10% | 1399764 2.7129% | $8.69M | 0 | 2 | |
| Michigan Biologic Products, Inc. | Member 13(d) group owning >10% | 1269390 2.4602% | $7.88M | 0 | 39 | |
| El-Hibri Fuad | Chairman | 1123988 2.1784% | $6.98M | 0 | 143 | |
| PAPA JOSEPH C | President and CEO | 342500 0.6638% | $2.13M | 1 | 0 | +48.13% |
| Abdun-Nabi Daniel | CEO | 142617 0.2764% | $885,651.57 | 2 | 48 | +25.65% |
| Kramer Robert | President and CEO | 139210 0.2698% | $864,494.10 | 0 | 34 | |
| Fowler Neal Franklin | director | 101100 0.1959% | $627,831.00 | 0 | 1 | |
| White Marvin L | director | 54092 0.1048% | $335,911.32 | 0 | 2 | |
| SULLIVAN LOUIS W | director | 42762 0.0829% | $265,552.02 | 0 | 8 | |
| LINDAHL RICHARD S | EVP, Chief Financial Officer | 39919 0.0774% | $247,896.99 | 1 | 0 | <0.0001% |
| Havey Adam | EVP, Business Operations | 38190 0.074% | $237,159.90 | 1 | 24 | +10.39% |
| JOULWAN GEORGE A | director | 26771 0.0519% | $166,247.91 | 0 | 7 | |
| Labinger Barry | EVP, Biosciences Div. | 25182 0.0488% | $156,380.22 | 0 | 3 | |
| Harsanyi Zsolt | director | 24579 0.0476% | $152,635.59 | 0 | 18 | |
| Bailey Sue | director | 24427 0.0473% | $151,691.67 | 0 | 12 | |
| Elsey R Don | Chief Financial Officer | 22199 0.043% | $137,855.79 | 1 | 9 | <0.0001% |
| Kirk Sean | EVP, Manufacturing & Tech Ops | 12571 0.0244% | $78,065.91 | 0 | 1 | |
| Hauer Jerome M | director | 10188 0.0197% | $63,267.48 | 0 | 16 | |
| Keese Kyle | SVP, Mfg Ops | 9070 0.0176% | $56,324.70 | 0 | 27 | |
| LOCKHART STEPHEN | SVP Product Development | 6980 0.0135% | $43,345.80 | 0 | 3 | |
| Zink Thomas | SVP & CMO | 990 0.0019% | $6,147.90 | 2 | 0 | <0.0001% |
| Esposito Denise | CLO | 500 0.001% | $3,105.00 | 0 | 2 | |
| Chatfield Steven | EVP, BioSciences | 0 0% | $0 | 0 | 3 | |
| Gibellini Mauro | SVP, Corporate Dev. | 0 0% | $0 | 0 | 1 |
$2,096,747 | 2095 | -11.76% | $101.74M | |
$131,310,609 | 62 | 26.99% | $220.03M | |
$2,767,882 | 51 | 8.70% | $33.33M | |
$30,221,759 | 51 | 0.50% | $25.58M | |
$102,709,455 | 46 | 30.55% | $1.04B | |
$33,884,330 | 45 | 12.56% | $235.97M | |
$98,035,963 | 43 | -10.97% | $612.45M | |
$6,021,989 | 30 | -0.17% | $669.99M | |
$32,539,771 | 28 | 33.37% | $371.01M | |
$123,153,600 | 23 | -21.26% | $31.52M | |
$25,034,841 | 20 | 9.38% | $701.25M | |
$1,842,055 | 12 | 35.28% | $503.24M | |
$1,843,996 | 10 | 22.92% | $1.02B | |
$758,061 | 9 | 60.03% | $216.32M | |
$26,633,903 | 9 | 42.23% | $763.17M | |
$155,341 | 9 | -22.42% | $62.28M | |
Emergent BioSolutions Inc. (EBS) | $529,315 | 8 | 7.33% | $320.41M |
$827,573 | 8 | -16.64% | $344.1M | |
$12,300,713 | 4 | 24.14% | $165.04M |
| Increased Positions | 103 | +54.21% | 5M | +12.93% |
| Decreased Positions | 80 | -42.11% | 4M | -8.54% |
| New Positions | 42 | New | 2M | New |
| Sold Out Positions | 28 | Sold Out | 1M | Sold Out |
| Total Postitions | 213 | +12.11% | 43M | +4.39% |
| Blackrock, Inc. | $53,332.00 | 8.04% | 4.26M | -97,752 | -2.24% | 2025-09-30 |
| Oak Hill Advisors Lp | $45,203.00 | 6.82% | 3.61M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $44,294.00 | 6.68% | 3.54M | -43,543 | -1.22% | 2025-09-30 |
| State Street Corp | $30,596.00 | 4.62% | 2.45M | +705,004 | +40.5% | 2025-09-30 |
| American Century Companies Inc | $29,804.00 | 4.5% | 2.38M | +90,216 | +3.94% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $26,776.00 | 4.04% | 2.14M | +291,308 | +15.76% | 2025-09-30 |
| Palisade Capital Management, Lp | $17,839.00 | 2.69% | 1.43M | +326,260 | +29.67% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $17,286.00 | 2.61% | 1.38M | +276,566 | +25.02% | 2025-09-30 |
| Geode Capital Management, Llc | $15,996.00 | 2.41% | 1.28M | -305 | -0.02% | 2025-09-30 |
| Acadian Asset Management Llc | $14,733.00 | 2.22% | 1.18M | +203,071 | +20.84% | 2025-09-30 |